Cardiol Total Current Liabilities vs Net Working Capital Analysis

CRDL Stock  USD 1.33  0.03  2.21%   
Cardiol Therapeutics financial indicator trend analysis is way more than just evaluating Cardiol Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiol Therapeutics is a good investment. Please check the relationship between Cardiol Therapeutics Total Current Liabilities and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Total Current Liabilities vs Net Working Capital

Total Current Liabilities vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiol Therapeutics Total Current Liabilities account and Net Working Capital. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Cardiol Therapeutics' Total Current Liabilities and Net Working Capital is 0.98. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Cardiol Therapeutics Class, assuming nothing else is changed. The correlation between historical values of Cardiol Therapeutics' Total Current Liabilities and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Cardiol Therapeutics Class are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Current Liabilities i.e., Cardiol Therapeutics' Total Current Liabilities and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.98
Relationship DirectionPositive 
Relationship StrengthVery Strong

Total Current Liabilities

Total Current Liabilities is an item on Cardiol Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cardiol Therapeutics Class are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Working Capital

Most indicators from Cardiol Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
The value of Selling General Administrative is expected to slide to about 14.6 M. The value of Issuance Of Capital Stock is estimated to slide to about 39.4 M
 2021 2022 2023 2024 (projected)
Depreciation And Amortization220.4K219.9K195.3K182.4K
Interest Income106.0K1.2M2.2M2.3M

Cardiol Therapeutics fundamental ratios Correlations

-0.670.840.961.00.960.55-1.0-0.760.791.0-0.290.711.00.490.73-0.720.820.960.961.00.96-0.80.910.55-0.74
-0.67-0.52-0.71-0.66-0.59-0.490.710.65-0.63-0.710.18-0.31-0.71-0.19-0.750.96-0.65-0.71-0.59-0.67-0.590.65-0.68-0.490.7
0.84-0.520.740.850.760.42-0.84-0.40.390.85-0.020.410.850.290.4-0.570.50.740.760.840.76-0.480.630.42-0.49
0.96-0.710.740.950.980.54-0.97-0.860.90.97-0.410.740.970.390.87-0.740.921.00.980.970.98-0.90.980.55-0.79
1.0-0.660.850.950.940.55-0.99-0.740.760.99-0.260.70.990.510.7-0.720.790.950.941.00.94-0.780.890.55-0.73
0.96-0.590.760.980.940.57-0.95-0.840.870.95-0.360.80.950.460.83-0.650.910.981.00.961.0-0.890.970.57-0.78
0.55-0.490.420.540.550.57-0.52-0.660.50.510.420.80.510.760.54-0.690.710.540.570.550.56-0.750.651.0-0.91
-1.00.71-0.84-0.97-0.99-0.95-0.520.77-0.8-1.00.34-0.67-1.0-0.42-0.750.75-0.82-0.97-0.95-1.0-0.950.8-0.91-0.510.73
-0.760.65-0.4-0.86-0.74-0.84-0.660.77-0.91-0.760.39-0.8-0.76-0.46-0.910.69-0.95-0.86-0.84-0.76-0.840.97-0.93-0.660.9
0.79-0.630.390.90.760.870.5-0.8-0.910.8-0.520.780.80.380.95-0.650.950.90.870.790.87-0.930.950.5-0.77
1.0-0.710.850.970.990.950.51-1.0-0.760.8-0.330.671.00.420.75-0.740.820.970.951.00.95-0.80.910.51-0.73
-0.290.18-0.02-0.41-0.26-0.360.420.340.39-0.52-0.33-0.03-0.330.38-0.45-0.01-0.31-0.42-0.36-0.29-0.370.27-0.350.43-0.03
0.71-0.310.410.740.70.80.8-0.67-0.80.780.67-0.030.670.70.69-0.490.880.740.790.710.79-0.890.840.8-0.85
1.0-0.710.850.970.990.950.51-1.0-0.760.81.0-0.330.670.420.75-0.740.820.970.951.00.95-0.80.910.51-0.73
0.49-0.190.290.390.510.460.76-0.42-0.460.380.420.380.70.420.31-0.390.460.390.460.490.46-0.520.490.76-0.63
0.73-0.750.40.870.70.830.54-0.75-0.910.950.75-0.450.690.750.31-0.740.940.870.830.730.83-0.920.920.54-0.8
-0.720.96-0.57-0.74-0.72-0.65-0.690.750.69-0.65-0.74-0.01-0.49-0.74-0.39-0.74-0.72-0.73-0.64-0.72-0.640.73-0.74-0.690.82
0.82-0.650.50.920.790.910.71-0.82-0.950.950.82-0.310.880.820.460.94-0.720.920.910.820.91-0.990.980.71-0.91
0.96-0.710.741.00.950.980.54-0.97-0.860.90.97-0.420.740.970.390.87-0.730.920.980.970.98-0.890.980.54-0.79
0.96-0.590.760.980.941.00.57-0.95-0.840.870.95-0.360.790.950.460.83-0.640.910.980.961.0-0.890.970.57-0.77
1.0-0.670.840.971.00.960.55-1.0-0.760.791.0-0.290.711.00.490.73-0.720.820.970.960.96-0.80.910.55-0.74
0.96-0.590.760.980.941.00.56-0.95-0.840.870.95-0.370.790.950.460.83-0.640.910.981.00.96-0.890.970.56-0.77
-0.80.65-0.48-0.9-0.78-0.89-0.750.80.97-0.93-0.80.27-0.89-0.8-0.52-0.920.73-0.99-0.89-0.89-0.8-0.89-0.97-0.750.94
0.91-0.680.630.980.890.970.65-0.91-0.930.950.91-0.350.840.910.490.92-0.740.980.980.970.910.97-0.970.65-0.87
0.55-0.490.420.550.550.571.0-0.51-0.660.50.510.430.80.510.760.54-0.690.710.540.570.550.56-0.750.65-0.91
-0.740.7-0.49-0.79-0.73-0.78-0.910.730.9-0.77-0.73-0.03-0.85-0.73-0.63-0.80.82-0.91-0.79-0.77-0.74-0.770.94-0.87-0.91
Click cells to compare fundamentals

Cardiol Therapeutics Account Relationship Matchups

Cardiol Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets15.5M15.9M87.9M62.0M36.7M38.6M
Short Long Term Debt Total190.8K156.6K117.6K72.9K174.3K133.9K
Other Current Liab640.1K696.1K7.4M1.4M655.0K622.2K
Total Current Liabilities690.5K2.5M11.6M9.8M8.3M5.5M
Total Stockholder Equity14.7M13.3M76.2M52.2M28.2M33.0M
Net Tangible Assets14.1M12.8M75.9M51.9M59.7M32.7M
Property Plant And Equipment Net584.0K479.6K356.5K295.7K337.1K329.6K
Net Debt(6.8M)(13.9M)(83.8M)(59.4M)(34.8M)(36.5M)
Retained Earnings(31.2M)(51.9M)(83.5M)(114.4M)(142.6M)(135.4M)
Accounts Payable561.3K1.8M4.1M8.3M7.6M3.9M
Cash7.0M14.0M83.9M59.5M34.9M34.3M
Non Current Assets Total1.1M943.2K735.7K590.5K547.4K610.6K
Cash And Short Term Investments7.0M14.0M83.9M59.5M34.9M34.3M
Net Receivables927.9K219.9K407.1K480.2K279.9K452.2K
Common Stock Shares Outstanding25.8M29.9M43.2M62.5M64.5M41.5M
Liabilities And Stockholders Equity15.5M15.9M87.9M62.0M36.7M38.6M
Non Current Liabilities Total140.3K104.7K72.9K22.4K158.5K109.5K
Other Stockholder Equity4.8M8.8M12.7M15.6M18.8M10.0M
Total Liab830.8K2.6M11.6M9.8M8.5M5.7M
Net Invested Capital14.7M13.3M76.2M52.2M60.0M33.4M
Total Current Assets14.4M14.9M87.1M61.4M36.2M37.8M
Net Working Capital13.7M12.4M75.6M51.6M59.4M32.5M
Intangible Assets548.1K463.7K379.2K294.8K210.4K371.0K
Common Stock39.4M51.9M142.9M147.5M148.5M89.8M
Property Plant Equipment584.0K479.6K356.5K295.7K340.1K322.7K
Inventory1.1M18.0K339.1K(279.9K)(251.9K)(239.3K)
Other Current Assets5.4M347.8K2.8M1.5M1.2M1.6M
Capital Stock39.4M51.9M142.9M147.5M169.7M92.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.38)
Return On Assets
(0.54)
Return On Equity
(1.08)
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.